Incyte (INCY) Competitors

$98.56 +0.79 (+0.81%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$98.50 -0.06 (-0.06%)

As of 05/8/2026 07:58 PM Eastern

INCY vs. ABBV, ALNY, BIIB, UTHR, and NBIX

Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.

How does Incyte compare to AbbVie?

Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92
AbbVie	$61.16B	5.82	$4.23B	$2.03	99.13

97.0% of Incyte shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 17.8% of Incyte shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Incyte has a net margin of 26.71% compared to AbbVie's net margin of 5.79%. Incyte's return on equity of 26.66% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
AbbVie	5.79%	-911.57%	13.43%

Incyte has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

In the previous week, AbbVie had 30 more articles in the media than Incyte. MarketBeat recorded 50 mentions for AbbVie and 20 mentions for Incyte. AbbVie's average media sentiment score of 1.13 beat Incyte's score of 0.70 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	35 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte currently has a consensus target price of $104.26, suggesting a potential upside of 5.79%. AbbVie has a consensus target price of $252.90, suggesting a potential upside of 25.67%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

AbbVie beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Incyte. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 20 mentions for Incyte. Incyte's average media sentiment score of 0.70 beat Alnylam Pharmaceuticals' score of 0.40 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.61	$313.75M	$3.66	80.61
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Alnylam Pharmaceuticals presently has a consensus target price of $471.96, suggesting a potential upside of 59.96%. Incyte has a consensus target price of $104.26, suggesting a potential upside of 5.79%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has a net margin of 26.71% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Incyte	26.71%	26.66%	19.77%

Summary

Incyte beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to Biogen?

Biogen (NASDAQ:BIIB) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Incyte has a net margin of 26.71% compared to Biogen's net margin of 13.81%. Incyte's return on equity of 26.66% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Incyte	26.71%	26.66%	19.77%

Biogen presently has a consensus target price of $214.23, indicating a potential upside of 10.74%. Incyte has a consensus target price of $104.26, indicating a potential upside of 5.79%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biogen is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

87.9% of Biogen shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biogen had 21 more articles in the media than Incyte. MarketBeat recorded 41 mentions for Biogen and 20 mentions for Incyte. Biogen's average media sentiment score of 0.92 beat Incyte's score of 0.70 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Biogen has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Biogen has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.89	$1.29B	$9.32	20.76
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92

Summary

Biogen beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to United Therapeutics?

Incyte (NASDAQ:INCY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Incyte currently has a consensus target price of $104.26, suggesting a potential upside of 5.79%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 9.64%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92
United Therapeutics	$3.18B	7.54	$1.33B	$27.09	20.85

In the previous week, United Therapeutics had 12 more articles in the media than Incyte. MarketBeat recorded 32 mentions for United Therapeutics and 20 mentions for Incyte. Incyte's average media sentiment score of 0.70 beat United Therapeutics' score of 0.53 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	16 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 17.8% of Incyte shares are owned by insiders. Comparatively, 10.3% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.

How does Incyte compare to Neurocrine Biosciences?

Incyte (NASDAQ:INCY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 17.8% of Incyte shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 21.55%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Incyte currently has a consensus target price of $104.26, suggesting a potential upside of 5.79%. Neurocrine Biosciences has a consensus target price of $184.15, suggesting a potential upside of 20.95%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82

Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92
Neurocrine Biosciences	$2.86B	5.35	$478.60M	$6.49	23.46

In the previous week, Neurocrine Biosciences had 23 more articles in the media than Incyte. MarketBeat recorded 43 mentions for Neurocrine Biosciences and 20 mentions for Incyte. Incyte's average media sentiment score of 0.70 beat Neurocrine Biosciences' score of 0.65 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Neurocrine Biosciences	12 Very Positive mention(s)	3 Positive mention(s)	18 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Summary

Incyte beats Neurocrine Biosciences on 10 of the 17 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.53B	$3.37B	$6.25B	$12.12B
Dividend Yield	N/A	2.25%	2.78%	5.20%
P/E Ratio	13.92	15.36	20.64	25.39
Price / Sales	3.83	298.52	534.02	75.96
Price / Cash	15.82	124.38	43.29	53.47
Price / Book	3.50	7.32	9.98	6.81
Net Income	$1.29B	$24.17M	$3.54B	$333.04M
7 Day Performance	1.70%	2.10%	3.50%	3.15%
1 Month Performance	1.65%	4.39%	4.17%	7.12%
1 Year Performance	67.11%	78.56%	41.85%	41.21%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	4.1514 of 5 stars	$98.56 +0.8%	$104.26 +5.8%	N/A	$19.53B	$5.14B	13.92	2,844
ABBV AbbVie	4.9442 of 5 stars	$197.24 -0.7%	$253.19 +28.4%	N/A	$351.35B	$61.16B	83.58	57,000	Trending News Analyst Upgrade Analyst Revision
ALNY Alnylam Pharmaceuticals	4.3025 of 5 stars	$308.51 +1.0%	$472.78 +53.2%	N/A	$40.77B	$3.71B	180.42	2,770	Trending News Analyst Forecast Analyst Revision
BIIB Biogen	3.8122 of 5 stars	$180.67 -2.0%	$211.81 +17.2%	N/A	$27.06B	$9.89B	20.51	7,500	Trending News Analyst Revision
UTHR United Therapeutics	3.2907 of 5 stars	$566.99 0.0%	$601.50 +6.1%	N/A	$24.86B	$3.18B	20.32	1,400	Trending News Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors

INCY vs. ABBV, ALNY, BIIB, UTHR, and NBIX

How does Incyte compare to AbbVie?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Summary

How does Incyte compare to Biogen?

Summary

How does Incyte compare to United Therapeutics?

Summary

How does Incyte compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incyte (INCY) Competitors

INCY vs. ABBV, ALNY, BIIB, UTHR, and NBIX

How does Incyte compare to AbbVie?

Which has preferable earnings & valuation, INCY or ABBV?

Do institutionals and insiders hold more shares of INCY or ABBV?

Is INCY or ABBV more profitable?

Which has more risk and volatility, INCY or ABBV?

Does the media refer more to INCY or ABBV?

Do analysts prefer INCY or ABBV?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Do institutionals & insiders hold more shares of ALNY or INCY?

Does the media favor ALNY or INCY?

Which has preferable valuation & earnings, ALNY or INCY?

Which has more risk & volatility, ALNY or INCY?

Do analysts recommend ALNY or INCY?

Is ALNY or INCY more profitable?

Summary

How does Incyte compare to Biogen?

Is BIIB or INCY more profitable?

Do analysts recommend BIIB or INCY?

Do insiders & institutionals have more ownership in BIIB or INCY?

Does the media refer more to BIIB or INCY?

Which has more volatility and risk, BIIB or INCY?

Which has stronger earnings and valuation, BIIB or INCY?

Summary

How does Incyte compare to United Therapeutics?

Do analysts prefer INCY or UTHR?

Which has preferable earnings and valuation, INCY or UTHR?

Does the media favor INCY or UTHR?

Do institutionals & insiders have more ownership in INCY or UTHR?

Which has more volatility and risk, INCY or UTHR?

Is INCY or UTHR more profitable?

Summary

How does Incyte compare to Neurocrine Biosciences?

Do institutionals & insiders have more ownership in INCY or NBIX?

Is INCY or NBIX more profitable?

Do analysts prefer INCY or NBIX?

Which has preferable earnings and valuation, INCY or NBIX?

Does the media favor INCY or NBIX?

Which has more volatility and risk, INCY or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools